2-甲基-3,5-二溴吡啶 | 38749-87-0

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-甲基-3,5-二溴吡啶
• 中文别名: 3,5-二溴-2-甲基吡啶
• 英文名称: 3,5-dibromo-2-methylpyridine
• CAS: 38749-87-0
• 化学式: C₆H₅Br₂N
• 分子量: 250.92
• InChiKey: HFMNHHLYRNSTSB-UHFFFAOYSA-N

物化性质

• 沸点：
  227.9±35.0 °C(Predicted)
• 密度：
  1.911±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3,5-Dibromo-2-methylpyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3,5-Dibromo-2-methylpyridine
CAS number: 38749-87-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H5Br2N
Molecular weight: 250.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲基-3,5-二溴吡啶 在 偶氮二异丁腈 N-溴代丁二酰亚胺(NBS) 作用下， 以 四氯化碳 为溶剂， 反应 4.0h， 以55%的产率得到3,5-dibromo-2-bromomethyl-pyridine
  参考文献：
  名称：

  Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3

  摘要：

  融合杂三环化合物，使用这种化合物治疗激素敏感性疾病如前列腺癌的方法，以及含有这种化合物的药物组合物。

  公开号：

  US20050192310A1
• 作为产物：
  描述：

  紫藤提取物 在 亚硝酸特丁酯 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以42%的产率得到2-甲基-3,5-二溴吡啶
  参考文献：
  名称：

  Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3

  摘要：

  融合杂三环化合物，使用这种化合物治疗激素敏感性疾病如前列腺癌的方法，以及含有这种化合物的药物组合物。

  公开号：

  US20050192310A1

文献信息

• [EN] GCN2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE GCN2 ET LEURS UTILISATIONS
  申请人：MERCK PATENT GMBH

  公开号：WO2019148132A1

  公开（公告）日：2019-08-01

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。
• [EN] NOVE PHENYL/PYRIDINE SERIES SUBSTITUED BY HYDROXYETHYLAMINO FOR THE TREATMENT OF CANCER<br/>[FR] NOUVELLE SÉRIE PHÉNYLE/PYRIDINE SUBSTITUÉE PAR HYDROXYÉTHYLAMINO POUR LE TRAITEMENT DU CANCER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014106606A1

  公开（公告）日：2014-07-10

  The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and W are as described herein, compositions including the compounds and methods of using the compounds.

  本发明提供了具有通用公式(I)的新颖化合物，其中R1、R2、R3、R4、R5、R6、R7和W如本文所述，包括这些化合物的组合物以及使用这些化合物的方法。
• THERAPEUTIC COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20130281433A1

  公开（公告）日：2013-10-24

  Compounds disclosed herein including compounds of formula I′: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.

  本文披露的化合物包括公式I′的化合物及其盐。还提供了包含本文披露的化合物的药物组合物、制备本文披露的化合物的方法、用于制备本文披露的化合物的中间体以及使用本文披露的化合物治疗HIV感染的治疗方法。
• [EN] SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING<br/>[FR] INHIBITEURS DE SREBP COMPRENANT UN NOYAU CENTRAL À 6 CHAÎNONS
  申请人：CAPULUS THERAPEUTICS LLC

  公开号：WO2019148125A1

  公开（公告）日：2019-08-01

  Provided herein are compounds comprising a three-ring core, such as compounds of Formula (X), Formula (X-A), Formula (X-Ai), Formula (X-B), Formula (X-Bi), Formula (Z), Formula (Z-A), Formula (Z-Ai), Formula (Z-B), Formula (Z-Bi), Formula (I), Formula (I-A), Formula (I-Ai), Formula (I-B), and Formula (I-Bi), and pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Also provided herein are methods of inhibiting a component of the sterol regulatory element binding protein (SREBP) pathway, such as an SREBP or SREBP cleavage activating protein (SCAP), using these compounds, or pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Further provided are methods of treating a disorder in a subject in need thereof, such as liver disease, non-alcoholic steatohepatitis, insulin resistance, or cancer.

  本文提供了包含三环核的化合物，例如Formula（X），Formula（X-A），Formula（X-Ai），Formula（X-B），Formula（X-Bi），Formula（Z），Formula（Z-A），Formula（Z-Ai），Formula（Z-B），Formula（Z-Bi），Formula（I），Formula（I-A），Formula（I-Ai），Formula（I-B）和Formula（I-Bi），以及其药学上可接受的盐类、溶剂化合物、互变异构体、同位素或同分异构体。本文还提供了利用这些化合物或其药学上可接受的盐类、溶剂化合物、互变异构体、同位素或同分异构体来抑制类固醇调节元件结合蛋白（SREBP）途径的组分的方法，例如SREBP或SREBP裂解激活蛋白（SCAP）。此外，还提供了治疗患有肝病、非酒精性脂肪肝病、胰岛素抵抗或癌症等疾病的方法。
• [EN] PYRIDINE RINGS CONTAINING DERIVATIVES AS MALT1 INHIBITORS<br/>[FR] CYCLES PYRIDINE CONTENANT DES DÉRIVÉS SERVANT D'INHIBITEURS DE MALT1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020208222A1

  公开（公告）日：2020-10-15

  Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT 1. Such compounds are represented by Formula (I) as follows: Formula (I), wherein the variables are defined herein.

  揭示了一种用于治疗受MALT 1调节影响的疾病、综合征、症状和疾病的化合物、组合物和方法。这些化合物由以下的化学式（I）表示：化学式（I），其中变量在此处定义。